English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer in the world (1). In its treatment, the cure is provided by surgery and /or adjuvant radiotherapy (RT) or primary chemoradiotherapy (CRT) (2,3). Despite this, 5-year survival rates are around 50% (4,5). Local recurrence and distant metastasis are the main causes of failure. TNM staging has been established with a certain role in determining the prognosis of the disease. The anatomic spread of tumor predicts prognosis (3-5).

medical science and discovery

Prognostic value of baseline and posttreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in head and neck squamous cell carcinoma receiving chemoradiotherapy